Home › Companies › Arcutis Biotherapeutics, Inc. › 2025-2026

Arcutis Biotherapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Arcutis Biotherapeutics, Inc.’s Form 8-K, filed June 9, 2026 (Item 5.07 on EDGAR). Page generated October 18, 2026.

5Ballot items
304Asset managers
1,545Fund votes
June 5, 2026Meeting date

Results at a glance

Meeting of June 5, 2026: 5 items on Arcutis Biotherapeutics, Inc.’s Form 8-K, filed June 9, 2026: 5 without a stated outcome.

Material dissent

Elect Director: Patrick J. Heron 67% of votes cast Outcome not stated Director under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Arcutis Biotherapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Arcutis Biotherapeutics, Inc.

These tallies are Arcutis Biotherapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 9, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Arcutis Biotherapeutics, Inc. — official shareholder meeting results, meeting held June 5, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Patrick J. Heron	62,830,439	--	--	30,446,098	14,868,017	67%	Not verified	—
Elect Director: Neha Krishnamohan	74,956,903	--	--	18,319,634	14,868,017	80%	Not verified	—
Elect Director: Todd Franklin Watanabe	75,771,853	--	--	17,504,684	14,868,017	81%	Not verified	—
2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026	107,867,442	15,748	261,364	--	--	99.9%	Not verified	—
3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers	88,728,269	3,723,408	824,860	--	14,868,017	96%	Not verified	—

Source: Arcutis Biotherapeutics, Inc., Form 8-K, filed with the SEC on June 9, 2026 — read the filing on EDGAR.

How asset managers voted at the Arcutis Biotherapeutics, Inc. 2025-2026 meeting

Each item below shows how the 304 asset managers that disclosed a Arcutis Biotherapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Neha Krishnamohan

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD

FOR: 74,956,903WITHHELD: 18,319,634

Details: description as filed, official tally, votes by 87 asset managers

Description as filed by funds: Election of Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: Neha Krishnamohan

Arcutis Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Neha Krishnamohan”): 74,956,903 for, 18,319,634 withheld, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 87 asset managers below reported 26,182,809 for, 4,712,901 withheld, 50 abstained.

FORWITHHOLD

FOR: 26,182,809ABSTAIN: 50WITHHOLD: 4,712,901

Largest asset managers voting on “Election of Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their su” at Arcutis Biotherapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	6,849,997	50	55,434	For
State Street	3,804,213	0	4,442	For
BlackRock	3,277,010	0	0	For
Fidelity	2,954,046	0	53,100	For
Prudential/PGIM	2,217,792	0	3,298	For
OBERWEIS FUNDS	0	0	1,211,800	Withhold
American Century	0	0	1,120,551	Withhold
Charles Schwab	1,012,955	0	0	For
TIAA	870,242	0	0	For
FRANKLIN STRATEGIC SERIES	850,058	0	0	For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)	710,000	0	0	For
Federated Hermes	689,843	0	0	For
Franklin Custodian Funds	400,000	0	0	For
DRIEHAUS MUTUAL FUNDS	0	0	396,980	Withhold
First Trust	0	0	351,058	Withhold
Bridge Builder Trust	334,408	0	0	For
T. Rowe Price	281,489	0	0	For
Equitable	156,363	0	74,380	Mixed
AMG FUNDS	230,038	0	0	For
Jackson National	147,000	0	56,192	Mixed
AIG/SunAmerica	0	0	179,784	Withhold
BUFFALO FUNDS	173,306	0	0	For
Principal Exchange-Traded Funds	0	0	163,367	Withhold
Lincoln Financial	74,800	0	68,824	Mixed
Allspring	0	0	132,842	Withhold

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

2. Elect Director: Patrick J. Heron

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

67% Majority: yes · of votes cast

FOR 67%WITHHELD

FOR: 62,830,439WITHHELD: 30,446,098

Details: description as filed, official tally, votes by 87 asset managers

Description as filed by funds: Election of Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: Patrick J. Heron

Arcutis Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Patrick J. Heron”): 62,830,439 for, 30,446,098 withheld, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 67% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 87 asset managers below reported 22,200,421 for, 8,695,256 withheld, 83 abstained.

FORWITHHOLD

FOR: 22,200,421ABSTAIN: 83WITHHOLD: 8,695,256

Largest asset managers voting on “Election of Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their su” at Arcutis Biotherapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	6,849,964	83	55,434	For
State Street	7,680	0	3,800,975	Withhold
BlackRock	3,277,010	0	0	For
Fidelity	2,954,046	0	53,100	For
Prudential/PGIM	2,217,792	0	3,298	For
OBERWEIS FUNDS	0	0	1,211,800	Withhold
American Century	0	0	1,120,551	Withhold
Charles Schwab	1,012,955	0	0	For
TIAA	870,242	0	0	For
FRANKLIN STRATEGIC SERIES	850,058	0	0	For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)	710,000	0	0	For
Federated Hermes	689,843	0	0	For
Franklin Custodian Funds	400,000	0	0	For
DRIEHAUS MUTUAL FUNDS	0	0	396,980	Withhold
First Trust	0	0	351,058	Withhold
Bridge Builder Trust	334,408	0	0	For
T. Rowe Price	281,489	0	0	For
Equitable	156,363	0	74,380	Mixed
AMG FUNDS	230,038	0	0	For
Jackson National	147,000	0	56,192	Mixed
AIG/SunAmerica	0	0	179,784	Withhold
BUFFALO FUNDS	173,306	0	0	For
Principal Exchange-Traded Funds	0	0	163,367	Withhold
Lincoln Financial	0	0	143,624	Withhold
Allspring	0	0	132,842	Withhold

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

3. Elect Director: Todd Franklin Watanabe

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD

FOR: 75,771,853WITHHELD: 17,504,684

Details: description as filed, official tally, votes by 87 asset managers

Description as filed by funds: Election of Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: Todd Franklin Watanabe

Arcutis Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Todd Franklin Watanabe”): 75,771,853 for, 17,504,684 withheld, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 87 asset managers below reported 26,332,327 for, 4,563,385 withheld, 48 abstained.

FORWITHHOLD

FOR: 26,332,327ABSTAIN: 48WITHHOLD: 4,563,385

Largest asset managers voting on “Election of Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their su” at Arcutis Biotherapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	6,849,999	48	55,434	For
State Street	3,804,213	0	4,442	For
BlackRock	3,277,010	0	0	For
Fidelity	2,954,046	0	53,100	For
Prudential/PGIM	2,217,792	0	3,298	For
OBERWEIS FUNDS	0	0	1,211,800	Withhold
American Century	0	0	1,120,551	Withhold
Charles Schwab	1,012,955	0	0	For
TIAA	870,242	0	0	For
FRANKLIN STRATEGIC SERIES	850,058	0	0	For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)	710,000	0	0	For
Federated Hermes	689,843	0	0	For
Franklin Custodian Funds	400,000	0	0	For
DRIEHAUS MUTUAL FUNDS	0	0	396,980	Withhold
First Trust	0	0	351,058	Withhold
Bridge Builder Trust	334,408	0	0	For
T. Rowe Price	281,489	0	0	For
Equitable	230,743	0	0	For
AMG FUNDS	230,038	0	0	For
Jackson National	147,000	0	56,192	Mixed
AIG/SunAmerica	0	0	179,784	Withhold
BUFFALO FUNDS	173,306	0	0	For
Principal Exchange-Traded Funds	0	0	163,367	Withhold
Lincoln Financial	74,800	0	68,824	Mixed
Allspring	0	0	132,842	Withhold

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

4. 3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers

Outcome not verified Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 88,728,269AGAINST: 3,723,408

Details: description as filed, official tally, votes by 304 asset managers

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.

Arcutis Biotherapeutics, Inc.’s own tally for this item (“3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers”): 88,728,269 for, 3,723,408 against, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 86 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.” at Arcutis Biotherapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	6,905,472	6	3	For
State Street	3,808,655	0	0	For
BlackRock	3,277,010	0	0	For
Fidelity	3,007,146	0	0	For
Prudential/PGIM	2,221,090	0	0	For
OBERWEIS FUNDS	1,211,800	0	0	For
American Century	0	1,120,551	0	Against
Charles Schwab	1,012,955	0	0	For
TIAA	870,242	0	0	For
FRANKLIN STRATEGIC SERIES	850,058	0	0	For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)	710,000	0	0	For
Federated Hermes	689,843	0	0	For
Franklin Custodian Funds	400,000	0	0	For
DRIEHAUS MUTUAL FUNDS	396,980	0	0	For
First Trust	351,058	0	0	For
Bridge Builder Trust	334,408	0	0	For
T. Rowe Price	281,489	0	0	For
Equitable	230,743	0	0	For
AMG FUNDS	230,038	0	0	For
Jackson National	203,192	0	0	For
AIG/SunAmerica	179,784	0	0	For
BUFFALO FUNDS	173,306	0	0	For
Principal Exchange-Traded Funds	163,367	0	0	For
Lincoln Financial	143,624	0	0	For
Allspring	132,842	0	0	For

Fund voting reports, all 86 managers: 29,665,630 for, 1,218,642 against, 11,166 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 241 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.” at Arcutis Biotherapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
MONTANOVA CAPITAL, LLC	11,785,519	0	For
Polar Capital Holdings Plc	10,719,320	0	For
Frazier Life Sciences Management, L.P.	9,874,511	0	For
State Street	6,184,113	3,852	For
JENNISON ASSOCIATES LLC	4,294,741	0	For
Rubric Capital Management LP	4,151,354	0	For
BlackRock	3,670,107	656	For
GEODE CAPITAL MANAGEMENT, LLC	3,047,912	0	For
FRANKLIN ADVISERS INC	2,270,457	0	For
OBERWEIS ASSET MANAGEMENT INC/	1,365,941	0	For
Ensign Peak Advisors, Inc	1,244,387	0	For
American Century	0	1,242,708	Against
DRIEHAUS CAPITAL MANAGEMENT LLC	1,179,449	0	For
Janus Henderson	1,135,958	0	For
Candriam S.C.A.	0	1,086,651	Against
Federated Hermes	1,059,299	0	For
Charles Schwab	1,013,136	0	For
DE Shaw	986,579	0	For
BAMCO INC /NY/	930,000	0	For
Vanguard	927,750	0	For
Nuveen	900,216	0	For
Northern Trust	852,062	0	For
GW&K Investment Management, LLC	794,211	0	For
MPM BioImpact LLC	686,616	0	For
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	676,200	0	For

Institutional-manager reports, all 241 managers: 79,587,267 for, 2,981,555 against, 59 not voted. Showing the 25 largest; see all in the interactive database.

5. 2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the…

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 107,867,442AGAINST: 15,748

Details: description as filed, official tally, votes by 87 asset managers

Description as filed by funds: To ratify the selection, by the Audit Committee of the Company's Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.

Arcutis Biotherapeutics, Inc.’s own tally for this item (“2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 20”): 107,867,442 for, 15,748 against, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 87 asset managers below reported 30,884,596 for, 11,164 abstained.

FOR

FOR: 30,884,596ABSTAIN: 11,164

Largest asset managers voting on “To ratify the selection, by the Audit Committee of the Company's Board of Directors, of Ernst & Young LLP, as ” at Arcutis Biotherapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	6,905,480	1	For
State Street	3,808,655	0	For
BlackRock	3,277,010	0	For
Fidelity	3,007,146	0	For
Prudential/PGIM	2,221,090	0	For
OBERWEIS FUNDS	1,211,800	0	For
American Century	1,120,551	0	For
Charles Schwab	1,012,955	0	For
TIAA	870,242	0	For
FRANKLIN STRATEGIC SERIES	850,058	0	For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)	710,000	0	For
Federated Hermes	689,843	0	For
Franklin Custodian Funds	400,000	0	For
DRIEHAUS MUTUAL FUNDS	396,980	0	For
First Trust	351,058	0	For
Bridge Builder Trust	334,408	0	For
T. Rowe Price	281,489	0	For
Equitable	230,743	0	For
AMG FUNDS	230,038	0	For
Jackson National	203,192	0	For
AIG/SunAmerica	179,784	0	For
BUFFALO FUNDS	173,306	0	For
Principal Exchange-Traded Funds	163,367	0	For
Lincoln Financial	143,624	0	For
Allspring	132,842	0	For

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

Largest Arcutis Biotherapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 125,042,000 shares outstanding at the time of that meeting.

Fund voting reports: top Arcutis Biotherapeutics, Inc. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	5.52%
2	State Street	3.05%
3	BlackRock	2.62%
4	Fidelity	2.40%
5	Prudential/PGIM	1.78%
6	OBERWEIS FUNDS	0.97%
7	American Century	0.90%
8	Charles Schwab	0.81%
9	TIAA	0.70%
10	FRANKLIN STRATEGIC SERIES	0.68%

Institutional-manager reports: top Arcutis Biotherapeutics, Inc. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive…”, 2025-2026
#	Asset manager	% of shares outstanding
1	MONTANOVA CAPITAL, LLC	9.43%
2	Polar Capital Holdings Plc	8.57%
3	Frazier Life Sciences Management, L.P.	7.90%
4	State Street	4.95%
5	JENNISON ASSOCIATES LLC	3.43%
6	Rubric Capital Management LP	3.32%
7	BlackRock	2.94%
8	GEODE CAPITAL MANAGEMENT, LLC	2.44%
9	FRANKLIN ADVISERS INC	1.82%
10	OBERWEIS ASSET MANAGEMENT INC/	1.09%

Reported Arcutis Biotherapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Arcutis Biotherapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Suvretta Capital Management, LLC	7.63%	DEF14A
BlackRock	7.36%	13F
Patrick J. Heron	7.08%	DEF14A
Frazier Life Sciences VIII, L.P.	7.03%	DEF14A
Rubric Capital Management LP	6.62%	13G
Vanguard Group	5.80%	13F
State Street	5.04%	13F
PRUDENTIAL FINANCIAL INC	4.24%	13G
Jennison Associates LLC	3.98%	13G
Morgan Stanley	3.47%	13F

Percentages above are of 125,042,000 shares outstanding, as reported by Arcutis Biotherapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Arcutis Biotherapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At Arcutis Biotherapeutics, Inc.'s shareholder meeting held June 5, 2026, in the 2025-2026 proxy season, 304 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,545 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Arcutis Biotherapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 9, 2026.

Arcutis Biotherapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.